Genfit - ADR

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 24 , 202 3 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced its provisional financial calendar for 2023.

GENFIT Announces 2023 Financial Calendar

Lille (France ), Cambridge (Massachusetts, United States), Zurich (Switzerland) November 17, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, today announced the highlights from its Pipeline Day events reviewing the Company's clinical progress and recent strategic updates.

GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases

Lille, France; Cambridge, MA; November 10, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of September 30, 2022 and revenue for the first nine months of 20221.

GENFIT Reports Third Quarter 2022 Financial Information

Lille (France ), Cambridge (Massachusetts, United States), October 25 , 20 22 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it has developed NIS2+™, a next-generation technology for the diagnosis of at-risk Non-Alcoholic Steatohepatitis (NASH), and will be presenting results on NIS2+™‘s clinical performance in three poster presentations at The Liver Meeting® 2022 organized by the American Association for the Study of Liver Diseases (AASLD).

GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®

Lille (France ), Cambridge (Massachusetts, United States), September 29 , 20 22 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG (“Versantis”) under the terms announced in its press release on September 19, 2022.

GENFIT Announces Signature of the Share Purchase Agreement and the Completion of its Acquisition of Versantis

Lille (France), Cambridge, MA; September 28, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe and chronic liver diseases, today announced its first half-year 2022 financial results and provided a corporate update.

GENFIT Reports First Half-Year 2022 Financial Results and Provides Corporate Update

Lille, France; Cambridge, MA; September 19 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases.

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

Lille (France ), Cambridge (Massachusetts, United States), September 1 3 , 20 22 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GNS5611 (ezurpimtrostat), a novel clinical-stage autophagy/PPT1 inhibitor, for the treatment of cholangiocarcinoma.

FDA Grants GENFIT's GNS561 Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward.

Genfit S.A.: A 'Sum Of The Parts' Story

Lille, France; Cambridge , M A ; May 2 5 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the results of the Combined Shareholders Meeting which took place on May 25, 2022. The quorum on first convening amounted to 25.16% and shareholders approved all of the resolutions submitted by the Board of Directors.

GENFIT: May 25, 2022 Combined Shareholders Meeting results

Lille, France; Cambridge, M A ; May 1 1 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of March 31, 2022 and revenues for the first three months of 2022. Cash position

GENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)

Lille, France; Cambridge, M A ; April 29 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the filing of its 2021 Universal Registration Document with the Autorité des marchés financiers (AMF) and its Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC), as well as the availability of preparatory documents for its annual shareholders meeting on Wednesday May 25, 2022.

GENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022

Lille, France; Cambridge, M A ; April 20 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced that it published in the April 20, 2022 French legal announcements bulletin n°47 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 25, 2022, at 10:00am, at the Faculty of Pharmaceutical Sciences in Lille, located at Parc Eurasanté, 3 rue du Professeur Laguesse, 59000 Lille, France.

GENFIT Annual Combined General Meeting of May 25, 2022 — Availability of Preparatory Documents

GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock

Genfit SA (GNFT) CEO Pascal Prigent on Q4 2021 Results - Earnings Call Transcript

Lille, France; Cambridge, M A ; April 7 , 202 2 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced annual financial results for the year ended December 31, 2021. A summary of the consolidated financial statements is included below.

GENFIT Reports Full-Year 2021 Financial Results and Provides Corporate Update

Lille, France; Cambridge , M A ; February 2 6 , 202 1 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of December 31, 2021 and revenues for 20211.

GENFIT Announces Solid Revenues and Cash Position as of December 31, 2021

Lille, France; Cambridge, MA; January 24, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its provisional financial calendar for 2022.

GENFIT: 2022 Financial Calendar

The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT).

Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock.

How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)?

Bellerophon Therapeutics

X4 Pharmaceuticals Inc

Which biotech penny stocks are you watching right now? The post These Biotech Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

These Biotech Penny Stocks Exploded Today, Here's Why

Genfit (GNFT) stock is rocketing higher on Friday after the company signed an exclusive licensing agreement with Ipsen (IPSEY). The post GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters appeared first on InvestorPlace.

GNFT Stock Alert: 15 Things to Know About Biotech Penny Stock Genfit as Shares Go Gangbusters

Genfit SA (NASDAQ: GNFT) shares are trading higher after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. David Loew, Chief Executive Officer, Ipsen, said, "Today's announcement marks an exciting new stage in Ipsen's ambitions to expand our portfolio to support more people living with rare diseases around the world.

Why Genfit Shares Are Rising

Ipsen SA (OTC: IPSEY) has entered into a long-term strategic partnership to develop, manufacture, and commercialize and Genfit SA's (NASDAQ: GNFT) elafibranor for Primary Biliary Cholangitis (PBC).  Under the agreement, Ipsen will pay Genfit up to €480 million, including an upfront cash payment of €120 million and milestone payments up to €360 million, plus tiered double-digit royalties of up to 20%.

Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful

The stock price of Genfit SA (NASDAQ: GNFT) increased by 50% pre-market today. This is why it happened.

News for Genfit - ADR Stock (GNFT)